Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.BMC nephrology · 2020
   Article
2. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2020
   Review
3. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2013
   Article
4. Childhood nephrotic syndrome--current and future therapies.Nature reviews. Nephrology · 2012
   Review
5. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2011
   Article
6. Should we consider MMF therapy after rituximab for nephrotic syndrome?Pediatric nephrology (Berlin, Germany) · 2011
   Article
7. Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and ciclosporin.Pediatric nephrology (Berlin, Germany) · 2010
   Article
8. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.Pediatric nephrology (Berlin, Germany) · 2010
   Article
9. Rituximab in refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010
   Article

Corrections and comments

• Comment on
  Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as